Veterinary cardiologist, Dr. Hayley McDonald Explains All about Felicyn CA-1

Written By My Vet Candy

Hypertrophic cardiomyopathy (HCM) is the most common form of heart disease in cats, affecting an estimated 1 in 7 felines. This translates to approximately 15% of the cat population. 

Felycin®-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).Felycin®-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM. Read our detailer to learn more about Felycin-CA1.

Veterinary cardiologist, Dr. Hayley McDonald, explains all!


Disclosure statement: Through Vet Candy, Dr. Hayley McDonald received compensation for this video from PRN Pharmacal.

My Vet Candy https://myvetcandy.com
Previous

Current Practices in Diagnosing and Managing Canine Cognitive Dysfunction Syndrome
Next

When Vaccine Hesitancy Walks Into the Exam Room